ALARIS Medical Included in Russell 2000 Index.

Business Editors and Health/Medical Writers

ALARIS Medical Inc. (AMEX:AMI) confirms today in response to inquires that its common stock was included in the Russell 2000(R) Index (a component of the Russell 3000 Index) as of July 1, 2002.

The Russell 3000(R) Index is composed of the 3,000 largest U.S. companies listed by total market capitalization. The Russell 2000(R) Index is composed of the 2,000 smallest members of the 3000 Index. The Frank Russell Company reconstitutes these Indexes annually in July of each year based on total market capitalization determined as of May of that year.

The minimum market capitalization required to be included in the Russell 2000 Index currently is about $128 million. With 59.1 million shares outstanding, ALARIS exceeded this milestone at year-end 2001 when its common stock closed at $3.15 per share. On May 31 2002, when the current Index was constituted, ALARIS common stock closed at $5.85 per share. AMI closed on July 17, 2002 at $6.44 per share.

David Schlotterbeck, president and CEO said, "I am pleased that our financial performance is beginning to be recognized by the market. We are committed to continued growth as the leader in intravenous medication safety."

ALARIS Medical is pursuing a growth strategy by focusing on intravenous medication safety in the hospital. The Guardrails(TM) Safety Software is the foundation of ALARIS Medical's safety solution. The Guardrails(TM) Software resides in the MEDLEY(TM) Medication Safety System and functions at the bedside to perform a "test of reasonableness" before allowing infusion to begin. If a mistake is made in programming an IV infusion, the Guardrails(TM) Safety Software alerts the clinician that the dose is outside of the institution's established limits and provides the correct dose limits for the specific type of patient.

ALARIS Medical Inc., through its wholly owned operating company, ALARIS Medical Systems Inc., develops practical solutions for medication safety at the point of care. The company designs, manufactures and markets intravenous (IV) medication delivery and infusion therapy devices, needle-free disposables and related monitoring equipment. ALARIS Medical's "smart" technology, tools and services reduce the risks and costs of medication errors, and safeguard patients and clinicians. The company provides its products, professional and technical support and training services to over 5,000 hospital and health care systems, as well as alternative care sites in more than 120 countries through its direct sales force and distributors. With headquarters in San Diego, ALARIS Medical employs approximately 2,600 people worldwide and operates manufacturing facilities in the United States, Mexico and the United Kingdom.

This news release contains forward-looking statements as defined in the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Persons reading this release are cautioned that such forward-looking statements involve risks and uncertainties, including the effect of legislative and regulatory changes affecting the health care industry, the potential of increased levels of competition, technological changes, the dependence of ALARIS Medical upon the success of new products (including its proprietary Guardrails(TM) Safety Software and the MEDLEY(TM) Medication Safety System) and ongoing research and development efforts including obtaining regulatory approvals, restrictions contained in the instruments governing the company's indebtedness, and the significant leverage to which the company is subject. Such risk factors are detailed in the Securities and Exchange Commission filings of ALARIS Medical, Inc. and ALARIS Medical Systems Inc., including Forms 10-K for the year ended Dec. 31, 2001, and other filings. The company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.